Overview Adrecizumab in Cardiogenic Shock Status: Completed Trial end date: 2021-04-26 Target enrollment: Participant gender: Summary Cardiogenic shock is a serious medical condition with high mortality and morbidity. This trial assesses safety, tolerability and efficacy of Adrecizumab on top of standard of care in patients with cardiogenic shock. Phase: Phase 2/Phase 3 Details Lead Sponsor: Dr. med. Mahir Karakas